PriceTargets.com logo

Indivior - INDV Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 330
  • Forecasted Upside: -83.12%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 1,955 As of 01/27/2023 01:00 AM ET
▼ -7 (-0.36%)

This chart shows the closing price for INDV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Indivior Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INDV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INDV

Analyst Price Target is GBX 330
▼ -83.12% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Indivior in the last 3 months. The average price target is GBX 330, with a high forecast of GBX 330 and a low forecast of GBX 330. The average price target represents a -83.12% upside from the last price of GBX 1,955.

This chart shows the closing price for INDV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in Indivior. This rating has held steady since June 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/25/2022Morgan StanleyInitiated CoverageEqual WeightGBX 330
6/30/2021Numis SecuritiesReiterated RatingBuyGBX 320
1/28/2021Jefferies Financial GroupReiterated RatingBuyGBX 205
1/26/2021CitigroupReiterated RatingBuyGBX 185
1/19/2021Jefferies Financial GroupReiterated RatingBuyGBX 180
7/27/2020Jefferies Financial GroupUpgradeBuyGBX 70 ➝ GBX 200
7/22/2020CitigroupBoost TargetNeutralGBX 45 ➝ GBX 85
6/30/2020Jefferies Financial GroupReiterated RatingHold
6/17/2020Jefferies Financial GroupBoost TargetHoldGBX 39 ➝ GBX 70
2/25/2020CitigroupLower TargetNeutralGBX 58 ➝ GBX 45
1/21/2020Jefferies Financial GroupLower TargetHoldGBX 65 ➝ GBX 39
11/15/2019Jefferies Financial GroupReiterated RatingHold
11/7/2019CitigroupReiterated RatingNeutral
5/2/2019CitigroupReiterated RatingNeutralGBX 150
4/10/2019Royal Bank of CanadaReiterated RatingSector PerformGBX 130
4/10/2019Numis SecuritiesReiterated RatingBuy
2/18/2019Jefferies Financial GroupDowngradeHoldGBX 118 ➝ GBX 114
2/5/2019Numis SecuritiesReiterated RatingBuy
12/18/2018Numis SecuritiesReiterated RatingBuyGBX 180
12/12/2018Royal Bank of CanadaDowngradeSector Performer
11/21/2018Royal Bank of CanadaDowngradeOutperformGBX 350 ➝ GBX 130
11/2/2018Royal Bank of CanadaReiterated RatingOutperformGBX 350
10/15/2018CitigroupReiterated RatingNeutral
10/11/2018Jefferies Financial GroupLower TargetBuyGBX 250 ➝ GBX 245
9/27/2018Numis SecuritiesReiterated RatingBuyGBX 350
7/26/2018CitigroupLower TargetNeutralGBX 365 ➝ GBX 350
7/25/2018Numis SecuritiesUpgradeBuyGBX 380
7/25/2018Jefferies Financial GroupReiterated RatingBuy
7/17/2018CitigroupLower TargetNeutralGBX 500 ➝ GBX 365
7/11/2018Jefferies Financial GroupReiterated RatingBuyGBX 630 ➝ GBX 545
7/11/2018Numis SecuritiesDowngradeHold
6/19/2018Morgan StanleyLower TargetEqual weightGBX 455 ➝ GBX 398
6/15/2018Jefferies Financial GroupReiterated RatingBuyGBX 630
6/15/2018Royal Bank of CanadaReiterated RatingOutperformGBX 540 ➝ GBX 550
6/15/2018Numis SecuritiesReiterated RatingBuy
5/15/2018CitigroupDowngradeNeutralGBX 490 ➝ GBX 500
5/8/2018Jefferies Financial GroupBoost TargetBuyGBX 610 ➝ GBX 630
5/2/2018Numis SecuritiesReiterated RatingBuyGBX 600
4/9/2018Jefferies Financial GroupBoost TargetBuyGBX 500 ➝ GBX 610
4/3/2018Morgan StanleyBoost TargetEqual weightGBX 450 ➝ GBX 455
3/23/2018Royal Bank of CanadaReiterated RatingOutperformGBX 540
3/23/2018Numis SecuritiesReiterated RatingBuyGBX 600
3/16/2018Numis SecuritiesReiterated RatingBuyGBX 640
2/15/2018Numis SecuritiesReiterated RatingBuyGBX 640
(Data available from 1/29/2018 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
7/3/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/1/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Indivior logo
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Read More

Today's Range

Now: GBX 1,955
Low: 1,948.20
High: 1,970

50 Day Range

MA: GBX 1,830.95
Low: 1,685
High: 2,015.33

52 Week Range

Now: GBX 1,955
Low: 1,052
High: 2,020

Volume

169,903 shs

Average Volume

348,462 shs

Market Capitalization

£2.67 billion

P/E Ratio

8,886.36

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Indivior?

The following Wall Street research analysts have issued reports on Indivior in the last twelve months: Morgan Stanley.
View the latest analyst ratings for INDV.

What is the current price target for Indivior?

1 Wall Street analysts have set twelve-month price targets for Indivior in the last year. Their average twelve-month price target is GBX 330, suggesting a possible downside of 83.1%. Morgan Stanley has the highest price target set, predicting INDV will reach GBX 330 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of GBX 330 for Indivior in the next year.
View the latest price targets for INDV.

What is the current consensus analyst rating for Indivior?

Indivior currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in INDV, but not buy more shares or sell existing shares.
View the latest ratings for INDV.

What other companies compete with Indivior?

Other companies that are similar to Indivior include UDG Healthcare, Abcam, Dechra Pharmaceuticals, BTG and Oxford Nanopore Technologies. Learn More about companies similar to Indivior.

How do I contact Indivior's investor relations team?

Indivior's physical mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The specialty pharmaceutical company's listed phone number is +44-1753-217800. The official website for Indivior is indivior.com. Learn More about contacing Indivior investor relations.